{"schema_version":"secwatch.filing_event.v1","accession":"0001640455-23-000040","form_type":"8-K","ticker":null,"cik":"0001640455","company_name":"Jounce Therapeutics, Inc.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.960982+00:00","generated_at":"2026-06-17T15:02:49.312226+00:00","sec_items":["1.01","1.02","2.05","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Jounce to be acquired by Concentra for $1.85 cash + CVR per share; terminates Redx deal","bullets":["Concentra will acquire all Jounce shares via tender offer at $1.85 cash/share plus one CVR; ~75% premium to unaffected price.","CVR entitles holders to 80% of net proceeds from any license/disposition of JTX-8064, pimivalimab, vopratelimab, and two pre-clinical programs within 2 years of close.","Jounce terminates prior co-operation agreement with Redx (all-share merger) and RM3 merger agreement; no termination fees.","Jounce reduces workforce by ~84%; expects $6.5M in pre-tax charges in Q2 2023.","Tang Capital Partners, LP commits $100M equity to fund the transaction; offer expected to close in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001640455-23-000040","json":"https://secwatch.observer/filing/0001640455-23-000040.json","markdown":"https://secwatch.observer/filing/0001640455-23-000040.md","text":"https://secwatch.observer/filing/0001640455-23-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000040/0001640455-23-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000040/jnce-20230326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T15:02:49.312226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb007a2dfc6799961314a048b3361b799a372ac8","claim":"Jounce Therapeutics, Inc. entered into Agreement and Plan of Merger with Concentra Biosciences, LLC (effective 2023-03-26).","evidence_excerpt":"On March 26, 2023, Jounce Therapeutics, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Concentra Biosciences, LLC, a Delaware limited liability company (“Concentra”), and Concentra Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Concentra (“Merger Sub”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000040/0001640455-23-000040-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Concentra Biosciences, LLC"},{"label":"Effective","value":"2023-03-26"}],"fact_type":"material_agreement"},{"claim_id":"1e1908aa00905914178f67ef1ac9b4ac4afe4485","claim":"Jounce Therapeutics, Inc. announced a restructuring with charges of approximately $6.5 million (approximately 84% of its current employees).","evidence_excerpt":"On March 26, 2023, the Company committed to a course of action that would result in a reduction in force intended to preserve the Company’s current cash resources. The Company will reduce its workforce by approximately 84% of its current employees. As a result of the reduction in force, the Company estimates that it will incur aggregate pre-tax charges of approximately $6.5 million, primarily consisting of salary payable during applicable notice periods and severance, non-cash stock-based compensation expense, and other benefits.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000040/0001640455-23-000040-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $6.5 million"},{"label":"Headcount","value":"approximately 84% of its current employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}